We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Read MoreHide Full Article
Key Takeaways
FMS posted Q2 EPS of 52 cents, which beat estimates by 4% and grew 36.8% year over year.
FMS Q2 revenues rose 7% organically to $5.44B, with gross margin expanding 90 bps to 25.4%.
FMS guided low-single-digit revenue growth and high-teens to high-twenties EBIT growth in 2025.
Fresenius Medical Care AG & Co. (FMS - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 4%. The bottom line improved 36.8% year over year.
FMS’ Revenue Details
Revenues of $5.44 billion (EUR 4,792 million) beat the Zacks Consensus Estimate by 1.6%. The top line increased 1% year over year and 5% at constant currency (cc). Also, revenues were up 7% organically.
Per management, during the second quarter, divestitures realized as part of the portfolio optimization plan hurt revenue development by EUR 6 million. The full-year top-line numbers are anticipated to reflect 100 basis points of negative impact due to the portfolio optimization plan in 2024.
Shares of FMS gained nearly 2.2% in yesterday’s after-market trading. The stock has risen 7.9% year to date against the industry’s decline of 8.8%. The S&P 500 Index has increased 7.4% in the same period.
Image Source: Zacks Investment Research
Segmental Details
Fresenius Medical implemented a new operating model in 2024 and started reporting under two new segments, Care Delivery and Care Enablement.
Care Delivery
The segment’s revenues were down 3% on a year-over-year basis but up 1% at cc. However, revenues gained 4% on an organic basis.
Revenues in the U.S. markets declined 2% reportedly but gained 3% on an organic basis. The top line also improved 3% year over year at cc. Per management, unfavorable exchange rates along with increased mortality due to the severe flu season in the United States in the first months of the year hurt sales in the country. However, this was partially offset by an accelerated number of patient new starts, reimbursement rate increases and a favorable payor mix.
Per management, during the first quarter of 2025, U.S. same-market treatment growth remained flat year over year.
International sales declined 8% reportedly as well as at cc but gained 5% on an organic basis. The decline was due to divestments realized as part of the portfolio optimization plan, which was partially offset by organic growth. The organic growth was supported by accelerated same-market treatment growth of 1.7%.
Care Enablement
The segment’s revenues decreased 1% year over year reportedly but gained 3% at cc as well as organically. Volume growth and continued positive pricing momentum were offset by unfavorable exchange rate effects.
Margin Analysis
In the quarter under review, Fresenius Medical’s gross profit improved 4.2% year over year. The gross margin expanded 90 basis points (bps) to 25.4%.
Selling, general & administrative expenses increased 2.7% on a reported basis. Research and development expenses decreased 17.4% year over year.
Adjusted operating income improved 9.2% from the prior-year quarter’s level. The adjusted operating margin in the second quarter expanded 80 bps to 9.9%.
2025 Guidance
For 2025, Fresenius Medical continues to expect revenue growth to be positive, with a low-single-digit percent rate compared to the prior year. The company also expects operating income to grow by a high-teens to high-twenties percent rate compared to the prior year.
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
FMS exited the second quarter on a strong note, with its earnings and revenues surpassing their respective consensus estimate. Overall pricing momentum also supported growth in the Care Enablement segment. However, the effects of elevated mortality will likely continue to have a negative impact on sales.
Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 58 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 53 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 1050 million by 2027-end.
FMS’ continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources.
FMS’ Zacks Rank & Other Stocks to Consider
Fresenius Medical currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Revenues of $603.3 million outpaced the consensus mark by 11.5%. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Key Takeaways
Fresenius Medical Care AG & Co. (FMS - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of 52 cents, which surpassed the Zacks Consensus Estimate by 4%. The bottom line improved 36.8% year over year.
FMS’ Revenue Details
Revenues of $5.44 billion (EUR 4,792 million) beat the Zacks Consensus Estimate by 1.6%. The top line increased 1% year over year and 5% at constant currency (cc). Also, revenues were up 7% organically.
Per management, during the second quarter, divestitures realized as part of the portfolio optimization plan hurt revenue development by EUR 6 million. The full-year top-line numbers are anticipated to reflect 100 basis points of negative impact due to the portfolio optimization plan in 2024.
Shares of FMS gained nearly 2.2% in yesterday’s after-market trading. The stock has risen 7.9% year to date against the industry’s decline of 8.8%. The S&P 500 Index has increased 7.4% in the same period.
Image Source: Zacks Investment Research
Segmental Details
Fresenius Medical implemented a new operating model in 2024 and started reporting under two new segments, Care Delivery and Care Enablement.
Care Delivery
The segment’s revenues were down 3% on a year-over-year basis but up 1% at cc. However, revenues gained 4% on an organic basis.
Revenues in the U.S. markets declined 2% reportedly but gained 3% on an organic basis. The top line also improved 3% year over year at cc. Per management, unfavorable exchange rates along with increased mortality due to the severe flu season in the United States in the first months of the year hurt sales in the country. However, this was partially offset by an accelerated number of patient new starts, reimbursement rate increases and a favorable payor mix.
Per management, during the first quarter of 2025, U.S. same-market treatment growth remained flat year over year.
International sales declined 8% reportedly as well as at cc but gained 5% on an organic basis. The decline was due to divestments realized as part of the portfolio optimization plan, which was partially offset by organic growth. The organic growth was supported by accelerated same-market treatment growth of 1.7%.
Care Enablement
The segment’s revenues decreased 1% year over year reportedly but gained 3% at cc as well as organically. Volume growth and continued positive pricing momentum were offset by unfavorable exchange rate effects.
Margin Analysis
In the quarter under review, Fresenius Medical’s gross profit improved 4.2% year over year. The gross margin expanded 90 basis points (bps) to 25.4%.
Selling, general & administrative expenses increased 2.7% on a reported basis. Research and development expenses decreased 17.4% year over year.
Adjusted operating income improved 9.2% from the prior-year quarter’s level. The adjusted operating margin in the second quarter expanded 80 bps to 9.9%.
2025 Guidance
For 2025, Fresenius Medical continues to expect revenue growth to be positive, with a low-single-digit percent rate compared to the prior year. The company also expects operating income to grow by a high-teens to high-twenties percent rate compared to the prior year.
Fresenius Medical Care AG & Co. KGaA Price, Consensus and EPS Surprise
Fresenius Medical Care AG & Co. KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG & Co. KGaA Quote
Our Take
FMS exited the second quarter on a strong note, with its earnings and revenues surpassing their respective consensus estimate. Overall pricing momentum also supported growth in the Care Enablement segment. However, the effects of elevated mortality will likely continue to have a negative impact on sales.
Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 58 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 53 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 1050 million by 2027-end.
FMS’ continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources.
FMS’ Zacks Rank & Other Stocks to Consider
Fresenius Medical currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Medpace Holdings, Inc. (MEDP - Free Report) , West Pharmaceutical Services, Inc. (WST - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Medpace Holdings, sporting a Zacks Rank of 1 at present, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Revenues of $603.3 million outpaced the consensus mark by 11.5%. Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy).
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.